The End of Pancreatic Cancer Could Be Just Around the Corner
Preclinical data showed that LP-184 shrunk tumors in vivo by more than 90% in just 8 weeks.
Source: pharmacytimes.com
Page 4 - Lantern Pharma News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Lantern Pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Lantern Pharma Today - Breaking & Trending Today
FDA Grants Orphan Drug Designation to LP-284 for High-Grade B-Cell Lymphomas
The FDA has granted orphan drug designation to LP-284 for use in the treatment of patients with high-grade B-cell lymphoma harboring MYC and BCL2 rearrangements.
Source: onclive.com
FDA Grants Orphan Drug Designation to LP-284 for Treatment of HGBL With MYC, BCL2 Rearrangements
Currently, there is no established standard of care treatment approach of HGBL, with frontline interventions consisting of chemo-immunotherapies.
Source: pharmacytimes.com
FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-284 in High-Grade B-cell Lymphomas (HGBL)
The Orphan Drug Designation strengthens LP-284’s clinical development path and can provide for additional market exclusivity and commercial protection. Lantern has initiated a first-in-human...
Source: marketscreener.com
Lantern Pharma: FDA Grants Orphan Drug Designation For LP-284 In High-Grade B-cell Lymphomas
Lantern Pharma Inc. (LTRN) announced the FDA has granted LP-284 Orphan Drug Designation for the treatment of high-grade B-cell lymphoma with MYC and BCL2 rearrangements.
Source: rttnews.com